Risankizumab

A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...

This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...

An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...

This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.

This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...

An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...

Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...

Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.

Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...

Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.

This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...

Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.

A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from tradingview.com.

A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.

A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...

If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...

Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...

Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...

This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.

A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.

An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...

A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...